Thymosin Beta 4 (TB500) (20mg)

• Composition and format
Thymosin Beta 4 (TB500) (20 mg) is a research-grade peptide supplied as a 20 mg lyophilized powder in a single vial. The batch-specific Certificate of Analysis (COA) provides sequence confirmation, net peptide content, and formulation details to support method-level reproducibility and documentation control.

• Analytical verification
Each lot is qualified at 99%+ purity by high-performance liquid chromatography; identity is confirmed by mass spectrometry; and independent third-party laboratories corroborate in-house analytics to maintain traceable quality metrics appropriate for research use.

• Intended research use
TB500 is evaluated in controlled in-vitro systems interrogating actin-binding dynamics, cellular migration, extracellular matrix organization, and angiogenic pathway signaling. All technical communications are method-centric and do not imply diagnostic, therapeutic, performance, or clinical outcomes.

• Research characteristics and applications
This research peptide interacts with actin-binding domains and influences cytoskeletal organization and angiogenic pathway signaling. It is utilized in in-vitro systems designed to study cellular migration, tissue matrix modeling, and the regulation of soft-tissue structural components. Its activity profile provides a foundation for research focused on cell motility, vascular formation, and extracellular matrix coordination.

• Manufacturing and documentation
Alpha BioMed Labs manufactures this material in the United States under defined quality procedures and research-only labeling. COAs, raw-material provenance from vetted suppliers, and batch records are maintained to facilitate institutional procurement review and audit readiness.

Research Use Only (RUO) Statement
• For in-vitro research only
• Not for human or animal consumption
• Not for diagnostic or therapeutic use